MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma
Ganna Oliynyk,
María Victoria Ruiz-Pérez,
Lourdes Sainero-Alcolado,
Johanna Dzieran,
Hanna Zirath,
Héctor Gallart-Ayala,
Craig E. Wheelock,
Henrik J. Johansson,
Roland Nilsson,
Janne Lehtiö,
Marie Arsenian-Henriksson
Affiliations
Ganna Oliynyk
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden
María Victoria Ruiz-Pérez
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden
Lourdes Sainero-Alcolado
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden
Johanna Dzieran
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden
Hanna Zirath
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden; The Dental and Pharmacological Benefits Agency, 104 22 Stockholm, Sweden
Héctor Gallart-Ayala
Department of Medical Biochemistry and Biophysics (MBB), Karolinska Institutet, 171 65 Stockholm, Sweden; Metabolomics Unit, University of Lausanne – UNIL, Lausanne, Switzerland
Craig E. Wheelock
Department of Medical Biochemistry and Biophysics (MBB), Karolinska Institutet, 171 65 Stockholm, Sweden
Henrik J. Johansson
Department of Oncology-Pathology, Karolinska Institutet, 171 21 Solna, Sweden; Science for Life Laboratory, Cancer Proteomics Mass Spectrometry, 171 65 Stockholm, Sweden
Roland Nilsson
Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden; Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden; Division of Cardiovascular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden
Janne Lehtiö
Department of Oncology-Pathology, Karolinska Institutet, 171 21 Solna, Sweden; Science for Life Laboratory, Cancer Proteomics Mass Spectrometry, 171 65 Stockholm, Sweden
Marie Arsenian-Henriksson
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden; Corresponding author
Summary: In pediatric neuroblastoma, MYCN-amplification correlates to poor clinical outcome and new treatment options are needed for these patients. Identifying the metabolic adaptations crucial for tumor progression may be a promising strategy to discover novel therapeutic targets. Here, we have combined proteomics, gene expression profiling, functional analysis, and metabolic tracing to decipher the impact of MYCN on neuroblastoma cell metabolism. We found that high MYCN levels are correlated with altered expression of proteins involved in multiple metabolic processes, including enhanced glycolysis and increased oxidative phosphorylation. Unexpectedly, we discovered that MYCN-amplified cells showed de novo glutamine synthesis. Furthermore, inhibition of β-oxidation reduced the viability of MYCN-amplified cells in vitro and decreased tumor burden in vivo, while not affecting non-MYCN–amplified tumors. Our data provide information on metabolic processes in MYCN expressing tumors, which could be exploited for the development of novel targeted therapies. : Biological Sciences; Cell Biology; Cancer Subject Areas: Biological Sciences, Cell Biology, Cancer